title: Induced sputum in children with newly diagnosed mild asthma: the effect of 6 months of treatment with budesonide or disodium cromoglycate.
abstract: BACKGROUND
  There are few controlled studies on the effects of anti-inflammatory treatment on airway inflammation in newly diagnosed childhood asthma.
  
  
  METHODS
  Sixty children with newly diagnosed mild persistent asthma, 5-10 years of age, and 17 healthy control subjects were studied. Asthmatic children were randomized into an open study with two treatment groups: (1) budesonide 400 microg twice daily for 1 month, 200 microg twice daily for 5 months and (2) disodium cromoglycate (DSCG) 10 mg three-times daily for 6 months. All exacerbations were treated with budesonide 400 microg twice daily for 2 weeks. Symptoms and lung function were recorded throughout the study.
  
  
  RESULTS
  Sputum induction was safe and the overall success rate was 71%. This improved with age and decreased after treatment. At baseline, the asthmatic children had more eosinophils in blood (0.26 vs 0.18 x 10(9)/l, P = 0.03) and sputum (1.1 vs 0.0 %, P = 0.0001) than the control subjects. The numbers of sputum eosinophils correlated with bronchial responsiveness (R = -0.58, P = 0.0002). Eosinophils were higher in children with atopic asthma than with nonatopic asthma (P < 0.0001), and in children with a history wheezing than in children without wheezing (P = 0.02). Six months of budesonide treatment, but not of DSCG, improved lung function (P = 0.007), decreased symptoms (P = 0.007) and sputum eosinophils (P = 0.003). The effects of budesonide were pronounced in children with intense sputum eosinophilia (>3%).
  
  
  CONCLUSIONS
  Sputum eosinophilia is present in children with newly diagnosed mild persistent asthma. Treatment with inhaled budesonide, but not with DSCG, decreases sputum eosinophils along with clinical and functional improvement.
authors.affiliation: Division of Allergy, Department of Medicine, Helsinki University Central Hospital, FIN-00029 Huch, Helsinki, Finland.
authors.forename: P
authors.initials: P
authors.lastname: Rytilä
authors.forename: A S
authors.initials: AS
authors.lastname: Pelkonen
authors.forename: T
authors.initials: T
authors.lastname: Metso
authors.forename: K
authors.initials: K
authors.lastname: Nikander
authors.forename: T
authors.initials: T
authors.lastname: Haahtela
authors.forename: M
authors.initials: M
authors.lastname: Turpeinen
mesh_terms: D001249:Asthma / Q000188:drug therapy* / Q000276:immunology / Q000378:metabolism; D001944:Breath Tests; D019819:Budesonide / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D004205:Cromolyn Sodium / Q000627:therapeutic use*; D003430:Cross-Sectional Studies; D004804:Eosinophils / Q000187:drug effects* / Q000502:physiology; D005260:Female; D006801:Humans; D008137:Longitudinal Studies; D008297:Male; D009569:Nitric Oxide / Q000378:metabolism; D013183:Sputum / Q000166:cytology*
chemical_list: D009569:Nitric Oxide; D019819:Budesonide; D004205:Cromolyn Sodium